These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1640487)

  • 1. Multiparametric prognostic evaluation of biological factors in primary breast cancer.
    Spyratos F; Martin PM; Hacène K; Romain S; Andrieu C; Ferrero-Poüs M; Deytieux S; Le Doussal V; Tubiana-Hulin M; Brunet M
    J Natl Cancer Inst; 1992 Aug; 84(16):1266-72. PubMed ID: 1640487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
    J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
    Harbeck N; Alt U; Berger U; Krüger A; Thomssen C; Jänicke F; Höfler H; Kates RE; Schmitt M
    Clin Cancer Res; 2001 Sep; 7(9):2757-64. PubMed ID: 11555589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
    Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
    Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
    Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
    Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
    Isola J; Weitz S; Visakorpi T; Holli K; Shea R; Khabbaz N; Kallioniemi OP
    J Clin Oncol; 1993 Jan; 11(1):36-43. PubMed ID: 8093367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma.
    Göhring UJ; Scharl A; Thelen U; Ahr A; Crombach G
    Anticancer Res; 1996; 16(2):1011-8. PubMed ID: 8687092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Bontenbal M; Jänicke F; Klijn JG
    Cancer Res; 1992 Nov; 52(21):6101-5. PubMed ID: 1394237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
    Peyrat JP; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
    Clin Cancer Res; 1998 Jan; 4(1):189-96. PubMed ID: 9516970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.
    Harbeck N; Alt U; Berger U; Kates R; Krüger A; Thomssen C; Jänicke F; Graeff H; Schmitt M
    Int J Biol Markers; 2000; 15(1):79-83. PubMed ID: 10763146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol.
    Pujol P; Maudelonde T; Daures JP; Rouanet P; Brouillet JP; Pujol H; Rochefort H
    Cancer; 1993 Mar; 71(6):2006-12. PubMed ID: 8443752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
    Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer].
    Bouchet C; Spyratos F; Martin PM; Hacène K; Gentile A; Oglobine J
    Bull Cancer; 1994 Sep; 81(9):770-9. PubMed ID: 7703566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients.
    Pinto AE; André S; Soares J
    J Clin Pathol; 1999 Aug; 52(8):604-11. PubMed ID: 10645231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
    Schmitt M; Jänicke F; Graeff H
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cathepsin D and prognosis in breast cancer.
    Tandon AK; Clark GM; Chamness GC; Chirgwin JM; McGuire WL
    N Engl J Med; 1990 Feb; 322(5):297-302. PubMed ID: 2296271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer.
    Malmström P; Bendahl PO; Boiesen P; Brünner N; Idvall I; Fernö M;
    J Clin Oncol; 2001 Apr; 19(7):2010-9. PubMed ID: 11283134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.
    Allred DC; Clark GM; Elledge R; Fuqua SA; Brown RW; Chamness GC; Osborne CK; McGuire WL
    J Natl Cancer Inst; 1993 Feb; 85(3):200-6. PubMed ID: 8423624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.